About A002390

Founded: 1954
Employees: 940
CEO: Young-Jin Kim
WebsiteView website: www.handok.co.kr

HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products. In addition, the company engages in real estate leasing. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is headquartered in Seoul, South Korea.

Recent A002390 News & Updates

New Risk • Mar 13

New major risk - Dividend sustainability

The dividend is not well covered by earnings and cash flows. The company is paying a dividend despite being loss-making. The company is paying a dividend despite having no free cash flows. Dividend yield: 1.9% This is considered a major risk. Companies that pay out too much of their earnings and cash flows are at risk of having to reduce or cut their dividend in future. If earnings or cash flows stagnate or fall, then there may not be enough to maintain the same dividend. Or in extreme cases, companies may opt to dig into capital reserves or take on debt to maintain the dividend. For dividend paying companies, any reduction in the dividend can significantly impact the share price. Currently, the following risks have been identified for the company: Major Risks Dividend is not well covered by earnings and cash flows. Paying a dividend despite being loss-making. Paying a dividend despite having no free cash flows. Earnings have declined by 68% per year over the past 5 years. Minor Risk Market cap is less than US$100m (₩138.9b market cap, or US$93.0m).

Recent updates

No updates

HANDOK Inc. Stock Price

A002390 Share Price Performance

A002390 Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

HANDOK Inc. Key Details

About A002390

Recent A002390 News & Updates

New major risk - Dividend sustainability

Full year 2025 earnings released: ₩162 loss per share (vs ₩3,819 loss in FY 2024)

HANDOK's (KRX:002390) Dividend Will Be ₩200.00

Recent updates

HANDOK Inc. Competitors

Samsung BiologicsLtd

Celltrion

ALTEOGEN

Samsung Epis Holdings